Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Guardant Health, Inc.

< Previous 1 2 3 4 5 6 7 Next >
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
From Guardant Health, Inc.
Via Business Wire
Tickers GH
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Tickers GH
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Debt Exchange Transactions
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Tickers GH
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.